title: Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals.
abstract: We evaluated immunologic predictors of response to HBV vaccine administered in the presence or absence of GM-CSF in HIV infected individuals. We measured peripheral blood hematopoietic progenitor, monocyte and myeloid-derived suppressor cell (MDSC) frequencies, and expression of GMCSF receptor on monocytes and MDSCs, at baseline and 4weeks after immunization in relation to antibody response. We observed higher baseline progenitor and lower monocyte frequencies among week 16 antibody responders. Week 4 decline in MDSC frequency was associated with week 16 antibody response, while administration of GM-CSF was associated with preservation of these cells. No significant differences in GM-CSF receptor expression were observed in the presence vs. absence of GM-CSF. These findings are consistent with a positive role of progenitor cells and a potential negative role of monocytes in vaccine response. Additionally, GM-CSF augmented the preservation of peripheral blood MDSC, which may contribute to the lack of improved vaccine responses.
authors.affiliation: Case Western Reserve University, Cleveland, OH 44106, USA. dda3@case.edu
authors.forename: D D
authors.initials: DD
authors.lastname: Anthony
authors.forename: T
authors.initials: T
authors.lastname: Umbleja
authors.forename: J A
authors.initials: JA
authors.lastname: Aberg
authors.forename: M
authors.initials: M
authors.lastname: Kang
authors.forename: K
authors.initials: K
authors.lastname: Medvik
authors.forename: M M
authors.initials: MM
authors.lastname: Lederman
authors.forename: M G
authors.initials: MG
authors.lastname: Peters
authors.forename: M J
authors.initials: MJ
authors.lastname: Koziel
authors.forename: E T
authors.initials: ET
authors.lastname: Overton
mesh_terms: D000917:Antibody Formation; D000938:Antigen-Presenting Cells / Q000276:immunology; D018952:Antigens, CD34 / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000276:immunology; D006678:HIV / Q000276:immunology; D015658:HIV Infections / Q000276:immunology*; D006412:Hematopoietic Stem Cells / Q000276:immunology*; D006510:Hepatitis B Antibodies / Q000097:blood; D017325:Hepatitis B Vaccines / Q000009:adverse effects / Q000276:immunology*; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology*; D010865:Pilot Projects; D016187:Receptors, Granulocyte-Macrophage Colony-Stimulating Factor / Q000276:immunology
chemical_list: D018952:Antigens, CD34; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D018950:Lipopolysaccharide Receptors; D016187:Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor